SMSN 943.0 3.2859% TYT 2543.0 7.5037% SMSD 748.0 -1.5789% SMSN 894.0 -2.0811% RIGD 55.4 2.5926% RIGD 54.0 -1.8182% SHEL 2326.0 1.5056% AZN 10018.0 3.6309% BHP 1658.0 3.0134% HSBA 733.7 2.8744% ULVR 4570.0 1.4879% CYPC 40.8 0.0% RIO 4208.0 2.2103% LLPC 148.7 0.0% DGED 106.6745 2.4141% BP 341.6 2.598% SBID 87.5 2.3392% DGE 2060.0 2.2333% GSK 1275.0 0.8703% REL 3733.0 4.2155%
SMSN 943.0 3.2859% TYT 2543.0 7.5037% SMSD 748.0 -1.5789% SMSN 894.0 -2.0811% RIGD 55.4 2.5926% RIGD 54.0 -1.8182% SHEL 2326.0 1.5056% AZN 10018.0 3.6309% BHP 1658.0 3.0134% HSBA 733.7 2.8744% ULVR 4570.0 1.4879% CYPC 40.8 0.0% RIO 4208.0 2.2103% LLPC 148.7 0.0% DGED 106.6745 2.4141% BP 341.6 2.598% SBID 87.5 2.3392% DGE 2060.0 2.2333% GSK 1275.0 0.8703% REL 3733.0 4.2155%

blue-chip

Update on this NYSE- Listed Healthcare Stock: OHI

Apr 07, 2025 | Team Kalkine
Update on this NYSE- Listed Healthcare Stock: OHI
Image source: Shutterstock

OHI:NYSE
Investment Type
Large-cap
Risk Level
Action
Rec. Price (US$)

Omega Healthcare Investors, Inc

Omega Healthcare Investors, Inc. (NYSE: OHI) is a real estate investment trust (REIT) that focuses on healthcare-related real estate investments across the United States and the United Kingdom. The company operates through a single business segment, primarily providing capital and financing to the long-term care sector. Its portfolio is centered around skilled nursing facilities (SNFs) and assisted living facilities (ALFs), with additional investments in independent living facilities (ILFs), rehabilitation and acute care centers, and medical office buildings (MOBs).

As per our previous US Dividend Income Report published on ‘OHI’ on 26th March 2025, Kalkine provided an Buystance on the stock at USD 37.69 based on fundamental analysis and the stock price has now moved down by ~0.93% since then.

Noted below are the details of support and resistance levels provided in our previous report:

Xxxxxx Xxxxxx Xxxxxx

Xxxxxx Xxxxxx

Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx .

Xxxxxx Xxxxxx Xxxxxx Xxxxxx & Xxxxxx

  • Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx
  • Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx .

Xxxxxx Xxxxxx

Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx .

Xxxxxx

Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx .   


Disclaimer-

This report has been issued by Kalkine Limited (Company number 07903332), a private limited company, incorporated in England and Wales ("Kalkine”). Kalkine.co.uk and associated pages are published by Kalkine. Kalkine is authorised and regulated by the Financial Conduct Authority under reference number 579414.

The information in this report and on the Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of information contained in its reports, newsletters and websites.  All information represents our views at the date of publication and may change without notice. The information in this report does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products. Our reports contain non personalized recommendations to invest in securities and other financial products.

Kalkine does not offer financial advice based upon your personal financial situation or goals, and we shall not be held liable for any investment or trading losses you may incur by using the opinions expressed in our reports, publications, market updates, news alerts and corporate profiles. Kalkine does not intend to exclude any liability which it is not permitted to exclude under applicable law or regulation. Kalkine’s non-personalised advice does not in any way endorse or recommend individuals, investment products or services for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a professional authorised financial planner and adviser. You should be aware that the value of any investment and the income from it can go down as well as up and you may not get back the amount invested.

Please also read our Terms & Conditions for further information. Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this report or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Kalkine Media Limited, an affiliate of Kalkine, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website including entities covered in this report.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions